For receptor and HER2 status: 69% (20/29) were ER-positive and 31% (9/29) were ER-negative; 41.4% (12/29) were PR-positive, and 58.6%(17/29) were PR-negative; 20.7% (6/29) were HER2-positive and 79.3% (23/29) were HER2-negative; finally, 13.8% (4/29) were triple negative (IBC cases that were ER, PR and HER2- negative were considered triple negative breast cancer (TNBC), and non-triple negative breast cancer if any marker was positive) (Table 1). Here, ESR1 is linked to inflammatory breast carcinoma.